Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202730 | 0.86 | HRH3 (0.44) | HRH3GPR119LIPECDK1CDK4 | |
| SCHEMBL20069134 | 0.82 | TDO2 (0.43) | HRH3GPR119PDGFRBPDGFRA | |
| SCHEMBL20147451 | 0.78 | HRH3 (0.52) | HRH3GPR119 | |
| SCHEMBL22856982 | 0.78 | TDO2 (0.46) | HRH3GPR119LIPE | |
| SCHEMBL20205807 | 0.77 | HRH3 (0.51) | HRH3PDGFRBPDGFRACHEK1 | |
| SCHEMBL20147952 | 0.75 | CHRM4 (0.48) | HRH3 | |
| SCHEMBL10819391 | 0.74 | HRH3 (0.48) | HRH3LIPE | |
| Hydrochloric Acid SCHEMBL20138455 | 0.72 | PDGFRB (0.41) | PDGFRBPDGFRA | |
| SCHEMBL25503004 | 0.72 | HRH3 (0.49) | HRH3 | |
| SCHEMBL18822846 | 0.72 | HRH3 (0.56) | HRH3PDGFRBPDGFRACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HRH3 1000/4885GPR119 1905/4885LIPE 4758/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HRH3 1000/4885GPR119 1905/4885LIPE 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.